INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INmune Bio Inc.

In a report released today, Thomas Shrader from BTIG maintained a Hold rating on Inmune Bio. The company’s shares opened today at $1.84. According ...

Inmune Bio (INMB) Gets a Hold from BTIG

Inmune Bio ( ($INMB) ) has shared an announcement. On October 23, 2025, INmune Bio Inc. announced it will host a conference call on October 30, 202...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INMB	$1.51	+1.34%	296.76K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INMB	$1.51	+1.3%	296.76K
3
4
5
6

INMB

INMB

Dividend Overview

Get INmune Bio Inc. Data in Excel

Get INmune Bio Inc. Data in Excel